Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Cholangiocarcinoma 5Urinary Bladder Neoplasms 3Acrocephalosyndactylia 3Stomach Neoplasms 2Glioblastoma 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Upper Tract Urothelial Carcinomas 1Tumor With Alterations of the FGF-R 1Squamous Cell Carcinoma of Head and Neck 1Renal Pelvis and Ureter Urothelial Carcinoma 1Rectal Neoplasms 1Papillomavirus Infections 1Pancreatic Neoplasms 1Oncogenic osteomalacia 1Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Neoplasms 1Melanoma 1Lung Neoplasms 1Liver Neoplasms 1Hypophosphatemia 1Hematologic Neoplasms 1Glioma 1Colonic Neoplasms 1Central Nervous System Neoplasms 1Advanced Gastrointestinal Stromal Tumor (GIST) 1

Interventions

infigratinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Tumor With Alterations of the FGF-R × infigratinib × Clear all
NCT01697605 2020-12-08

A Phase I Study of Oral BGJ398 in Asian Patients

Novartis

Phase 1 Completed
9 enrolled

Tumor With Alterations of the FGF-R

Data powered by HemOnc (CC BY 4.0) Colophon âš¡